West Cancer Center & Research Institute, a leader in oncology care, has teamed up with EngagedMD, a leader in digital patient ...

A study found no significant HRQOL differences between Erleada-based therapies and ADT plus AAP for advanced castration-sensitive prostate cancer.

(RTTNews) - RedHill Biopharma (RDHL) Tuesday announced that it has launched a Phase 2 trial to assess opaganib's ability to enhance darolutamide in treating metastatic castrate-resistant prostate ...

There are currently, however, two radioligands that are United States Food and Drug Administration (FDA)-approved for the treatment of mCRPC patients: Patients with advanced prostate cancer are at ...

The Mount Sinai Hospital has performed New York City’s first procedure using the HYDROS™ Robotic System, a cutting-edge technology designed to treat benign prostatic hyperplasia (BPH), or an enlarged ...

They also discovered patients had a decrease in MDSCs. Increased number of polymorphonuclear MDSCs are associated with tumor growth and poor prognosis for men with prostate cancer. MDSCs can ...

From a Pro Football Hall of Famer announcing his diagnosis to an R&B star’s latest update, here’s what’s happening in the cancer space this week. A study showed that patients with prostate cancer ...

Establishing and Characterizing the Molecular Profiles, Cellular Features, and Clinical Utility of a Patient-Derived Xenograft Model Using Benign Prostatic Tissues - Beyond the Abstract ...

As an expert in translational genomics and pre-clinical therapeutics for prostate cancer, Feng’s research focused on the discovery of prognostic and predictive biomarkers to advance precision cancer ...

This innovative approach has gained attention for its potential to improve survival rates and quality of life for patients with advanced prostate cancer. Lutetium-177 is one of the most widely ...